JP2024507948A - 呼吸器ウイルス感染症に対する防御抗体 - Google Patents

呼吸器ウイルス感染症に対する防御抗体 Download PDF

Info

Publication number
JP2024507948A
JP2024507948A JP2023552013A JP2023552013A JP2024507948A JP 2024507948 A JP2024507948 A JP 2024507948A JP 2023552013 A JP2023552013 A JP 2023552013A JP 2023552013 A JP2023552013 A JP 2023552013A JP 2024507948 A JP2024507948 A JP 2024507948A
Authority
JP
Japan
Prior art keywords
seq
sequence
antibody
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023552013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507948A5 (https=
Inventor
ジェイ． テイラー，ジャスティン
ブーンヤラタナコーンキット，ジム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of JP2024507948A publication Critical patent/JP2024507948A/ja
Publication of JP2024507948A5 publication Critical patent/JP2024507948A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
JP2023552013A 2021-02-26 2022-02-25 呼吸器ウイルス感染症に対する防御抗体 Pending JP2024507948A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163154166P 2021-02-26 2021-02-26
US63/154,166 2021-02-26
PCT/US2022/017945 WO2022183018A1 (en) 2021-02-26 2022-02-25 Protective antibodies against respiratory viral infections

Publications (2)

Publication Number Publication Date
JP2024507948A true JP2024507948A (ja) 2024-02-21
JP2024507948A5 JP2024507948A5 (https=) 2025-03-05

Family

ID=83048466

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023552013A Pending JP2024507948A (ja) 2021-02-26 2022-02-25 呼吸器ウイルス感染症に対する防御抗体

Country Status (7)

Country Link
US (1) US20240150444A1 (https=)
EP (1) EP4297780A4 (https=)
JP (1) JP2024507948A (https=)
KR (1) KR20230148418A (https=)
AU (1) AU2022227761A1 (https=)
CA (1) CA3209869A1 (https=)
WO (1) WO2022183018A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
US20250304657A1 (en) * 2022-08-29 2025-10-02 Fred Hutchison Cancer Center Antibodies with novel fc modification combinations that increase antibody function
WO2024077268A2 (en) * 2022-10-07 2024-04-11 Fred Hutchinson Cancer Center Human metapneumovirus antibodies and uses thereof
WO2025165833A1 (en) * 2024-01-29 2025-08-07 Vanderbilt University Hpiv3-neutralizing antibodies and methods of use thereof
CN119039429B (zh) * 2024-08-27 2025-10-03 浙江大学 一种抗RBD单链抗体No.35及制备抗体偶联药物的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514068A (ja) * 2012-03-20 2015-05-18 フマブス バイオメッド エスアー Ｒｓｖ、ｍｐｖおよびｐｖｍを中和する抗体およびその利用
JP2020503844A (ja) * 2016-10-21 2020-02-06 アディマブ， エルエルシー 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2504364T3 (pl) * 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
WO2019165019A1 (en) * 2018-02-21 2019-08-29 Vanderbilt University Antibodies to human respiratory syncytial virus protein f pre-fusion conformation and methods of use therefor
US11066469B2 (en) * 2019-06-12 2021-07-20 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514068A (ja) * 2012-03-20 2015-05-18 フマブス バイオメッド エスアー Ｒｓｖ、ｍｐｖおよびｐｖｍを中和する抗体およびその利用
JP2020503844A (ja) * 2016-10-21 2020-02-06 アディマブ， エルエルシー 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NATURE, vol. 501, JPN6026004590, 2013, pages 439 - 443, ISSN: 0005793337 *

Also Published As

Publication number Publication date
KR20230148418A (ko) 2023-10-24
WO2022183018A1 (en) 2022-09-01
CA3209869A1 (en) 2022-09-01
US20240150444A1 (en) 2024-05-09
AU2022227761A9 (en) 2024-01-25
EP4297780A1 (en) 2024-01-03
EP4297780A4 (en) 2025-07-16
AU2022227761A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
TWI859420B (zh) 抗sars-cov-2抗體及使用其之方法
JP2024507948A (ja) 呼吸器ウイルス感染症に対する防御抗体
JP7498714B2 (ja) Ｂ型肝炎ウイルスを中和する抗体およびその使用
US20230331824A1 (en) Single-domain antibodies that bind sars-cov-2
US20240059757A1 (en) Antibodies against sars-cov-2 and methods of using the same
CN110621338B (zh) 广谱中和抗hiv-1抗体及其使用方法
JP2023528826A (ja) Ｓａｒｓ関連コロナウイルスに対する中和抗体
JP7717194B2 (ja) 呼吸器合胞体ウイルスに対する抗体及びその使用
WO2021247925A1 (en) Structure-guided immunotherapy against sars-cov-2
US20250188154A1 (en) Coronavirus antibodies and uses thereof
WO2021228904A1 (en) Neutralizing antibodies binding to the spike protein of sars-cov-2 suitable for use in the treatment of covid-19, compositions comprising the same and uses thereof
CN116096402A (zh) 与抗人冠状病毒的中和抗体相关的方法和组合物
WO2024209076A1 (en) Combined antibodies against sarbecoviruses and uses thereof
TW202423963A (zh) 針對ｒｓｖ及ｍｐｖ副黏液病毒之廣效中和抗體
TW202204395A (zh) 抗sars-cov-2之抗體及使用其之方法
WO2022060838A1 (en) Antibodies or antibody-fragments thereof targeting alphaviruses, and compositions and methods comprising same
RU2824390C2 (ru) Фармацевтическая композиция, содержащая антитело против il-5, и ее применение
WO2024211789A1 (en) Cross-flavivirus binding domains and uses thereof
WO2026030604A1 (en) Human anti-sars-cov-2 spike (s) antibodies
CN116724049A (zh) 针对sars相关冠状病毒的中和抗体
WO2024068996A1 (en) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
WO2025222144A1 (en) Antibodies and vaccines having vh3-21 and vl1-40 binding domains and uses thereof
HK40019070B (en) Broadly neutralizing anti-hiv-1 antibodies and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230825

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20250124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250225

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260210